Preparation and Characterization of Colon-Specific Microspheres of Diclofenac for Colorectal Cancer by Dang, T et al.
Dang et al 
Trop J Pharm Res, September 2015; 14(9): 1541  
 
Tropical Journal of Pharmaceutical Research September 2015; 14 (9): 1541-1547 
ISSN: 1596-5996 (print); 1596-9827 (electronic) 
© Pharmacotherapy Group, Faculty of Pharmacy, Univers ty of Benin, Benin City, 300001 Nigeria.  
All rights reserved. 
 
Available online at http://www.tjpr.org 
http://dx.doi.org/10.4314/tjpr.v14i9.1 
Original Research Article 
 
 
Preparation and Characterization of Colon-Specific 
Microspheres of Diclofenac for Colorectal Cancer 
 
Tong Dang, Ying Cui, Yan-Dong Chen, Xian-Mei Meng, Bo-Fu Tang and Jin-Bao 
Wu* 
Inner Mongolia Institute of Digestive Diseases, the Second Affiliated Hospital of Baotou Medical College, Baotou 014030, China 
 
*For correspondence: Email: wujinbao2143@gmail.com; Tel/Fax: 0086-472-3169715 
 
Received: 12 February 2015        Revised accepted: 26 July 2015 
 
Abstract 
Purpose: To prepare and evaluate colon specific drug delivery system of diclofenac sodium for highly 
localized delivery to the colon.  
Methods: The colon specific drug delivery system was prepared as matrix-type microspheres using 
Ethyl Cellulose (EC), Cellulose Acetate Phthalate (CAP), and Eudragit L 100-55 by the Solvent 
Evaporation Method. Microspheres were evaluated for physical properties like drug content, particle 
size, bulk density and angle of repose.  
Results: The size range of the microcapsules was 228 to 608 µm while drug content was between 
74.49 and 91.50 % depending on the polymer used and the polymer ratio. Mean bulk density was < 1.2 
g/ml which indicates the good flow properties, while angle of repose was < 40 o, indicating free-flowing 
properties. The microspheres were spherical in shape with smooth and nonporous surface, except that 
the microspheres containing EC and CAP exhibited a rough and porous surface. The microspheres 
containing Eudragit L 100-55 in combination with other polymers gave better sustained release (78.9 
and 76.6 % at the end of 8 h for formulation F4 and F5, respectively) than the others. 
Conclusion: Microspheres prepared with drug: EC: CAP ratio of 1:2:1 show the highest drug content, 
possess good flow properties and surface morphology, as well as promising drug release for colon 
specific drug delivery of diclofenac sodium for possible treatment of colorectal cancer. 
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The oral route of drug administration is the most 
convenient and important method of 
administering drugs for systemic effect due to 
patient acceptance and ease of administration. 
An oral colon specific drug delivery system is 
intended to retard the drug release in the 
stomach and small intestine, but allow complete 
release in colon for the various diseases like 
colorectal cancer and inflammatory bowel 
diseases [1-3]. Studies have consistently 
demonstrated that regular use (at least two 
doses per week) of nonsteroidal anti-
inflammatory drugs (NSAIDs) is associated with 
a reduced risk of colorectal cancer. 
Epidemiological studies have indicated that non-
steroidal anti-inflammatory drugs (NSAIDs), 
including indomethacin, aspirin, and sulindac, 
exhibit anti-cancer activity in colorectal cancer [4-
6].  
 
Colon specific drug delivery systems target the 
drug release in the colon only without being 
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dissolved/release in upper GIT. The drug should 
degrade neither in upper GIT nor in the colon 
(dissolution site) and should release the drug 
only after reaching the colon. The prerequisite is 
that the drug should be well absorbed from the 
colon (like glibenclamide, diclofenac, 
theophylline, ibuprofen, etc) [7]. 
 
Natural  polysaccharides  e.g. pectin, chitosan, 
guar gum, dextran, inulin, cyclodextrin, xanthum 
gum, etc are  extensively  used  for  the 
development  of  solid oral  dosage  forms  for  
colonic delivery  of  drugs [8]. There are various 
synthetic polymers which are used for colon 
targeted drug delivery. These can also be called 
as pH-dependent polymers.   
 
The most commonly used pH-dependent 
polymers are derivatives of acrylic acid and 
cellulose. The pH dependent polymers used in 
colon specific drug delivery are insoluble at low 
pH levels but become increasingly soluble as pH 
rises. e.g., Eudragit and shellac [9]. 
 
Microparticles are a type of  drug  delivery  
systems where  the  particle  size  ranges  from  
one micron  to  few   mm. Microspheres are 
characteristically free flowing powders consisting 
of proteins and synthetic polymers, 
biodegradable in nature and having a particle 
size less than 200 µm  (normally  the  range  is  
also  acceptable  up to  1000 – 1500 µm) [10]. 
 
Dicolofenac sodium (DS) is a well-known non-
steroidal anti-inflammatory drug (NSAID). It is 
well absorbed in the colon, and colon specific 
release can be used for the treatment of various 
diseases like colorectal cancer and inflammatory 
bowel diseases [11-13].  
 
Diclofenac is an effective agent in the cancer 
regression as the traditional NSAIDs (COX-1 
inhibitor) or specific COX-2 inhibitor [14].  
Diclofenac decreases inflammation at tissues 
sites and exert preventive effect against colon 
cancer that seems to be due to increased colon 
cell apoptosis [15]. As an alternative strategy of 
colorectal cancer treatment the colon specific 
delivery of NSAIDs like diclofenac is well 
accepted and investigated [16,17]. 
 
Therefore, the present study investigates the 
colon specific delivery of diclofenac sodium in 
matrix-type microspheres prepared with ethyl 
celluolose, cellulose acetate phthalate and 




Diclofenac sodium, sodium alginate, guar gum 
and xanthan gum were procured from Sigma 
Aldrich, USA. All other chemicals used were of 
analytical grade. 
 
Preparation of microspheres 
 
The microspheres of diclofenac sodium were 
prepared by solvent evaporation technique using 
ethyl cellulose, cellulose acetate phthalate (CAP) 
and Eudragit L 100-55 (Table 1). 
 
An accurately weighed amount of polymer was 
dissolved in 30 ml of acetone in a beaker. 
Weighed amount of Verapamil Hydrochloride, 
was dispersed, in this solution and stirred for 15 
min for complete dispersion. The dispersion was 
poured into 100 ml of light mineral oil containing 
1.3 % span 80 and stirred for 5 h at 1000 rpm 
using mechanical stirrer at room temperature. 
The light mineral oil was used as the 
microencapsulating vehicle and SPAN 80 as an 
emulsifying agent. During the 5 h stirring period, 
acetone was completely removed by 
evaporation. The light mineral oil was decanted 
and the collected microspheres were washed 
thrice with 50 ml of n-hexane at room 
temperature, after which the microcapsules were 
separated by filtration. The microcapsules were 
kept for 12 h at room temperature for drying and 
stored in desiccators for complete removal of 
moisture. 
 
Table 1: Composition of colon specific microspheres of diclofenac sodium 
 
Ingredient F1 F2 F3 F4 F5 F6 
Diclofenac sodium 1 1 1 1 1 1 
EC 3 ... 2 2.5 … 1 
CAP … 3 1 … 2.5 1 
Eudragit L100-55 ... … … 0.5 0.5 1 
Key:  EC = ethyl cellulose, CAP = cellulose acetate phthalate 
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Determination of yield  
 
The percentage yield was calculated from the 
weight of dried microspheres recovered from 
each batch in relation to the sum of the initial 
weight of starting materials. Yield was calculated 
using Eq 1. 
 
Yield (%) = (Mp/Mt)100 ……………………. (1) 
 
where Mp and Mt are the practical mass of 
microspheres and theoretical mass of polymer + 
drug, respectively. 
 




Using optical microscopy method particle size of 
the formulations was determined. At least 100 
microspheres were analyzed for each formulation 
and the mean particle size was calculated. 
 
Angle of repose  
 
The flow property of the prepared microcapsules 
was determined by the angle of repose, using 
fixed funnel method. The known quantities of 
microcapsules were passed through the funnel 
and the heap was formed on paper. The formed 
heap on paper was encircled. From the radius of 
the circle and height of the conical heap, angle of 
repose was calculated. 
 
Compressibility index  
 
The loose bulk density (ρb) and the tap (ρt) 
density of the microspheres were measured in a 
measuring cylinder [10,18]. An amount of 1 g of 
prepared microspheres was filled in 10 ml 
graduated cylinder. The initial volume was noted 
then cylinder was tapped on wooden surface. 
The density was measured by tapping the 
cylinder 100 times (from the height of one inch) 
at the rate of 240 taps/min. Each determination 
was carried out in triplicate and the densities 
were calculated from the mean of the three 
determinations. Density was calculated as the 
ratio of mass to volume, compressibility index 
(CI) using Eq 2 and Hausner’s ratio (HR) using 
Eq 3.  
 
CI = {(ρt – ρb)/ρt}100 …………………….… (2)  
 
HR = (ρt/ρb)100 …………………………..... (3) 
 
Evaluation of drug content  
 
The drug content was calculated by taking the 
microspheres equivalent to 100 mg of drug. 
Microspheres were finely crushed, dissolved in 
100 ml of methanol through stirring on magnetic 
stirrer for 1 h and then filtered. Then the sample 
was withdrawn, filtered, diluted suitably and 
measured spectrophotometrically (Lambda 25 
Perkin Elmer, UV/Visible Spectrophotometer, 
USA) at 276 nm for the drug content.  
 
Characterization of surface morphology 
 
To assess the surface morphology and particle 
size of the microspheres, SEM of the 
microspheres was performed by scanning 
electron microscope (Carl Zeiss SMT Evo 
Series). 
 
In vitro dissolution studies  
 
The release studies of diclofenac from 
microspheres were performed in USP dissolution 
apparatus type I, at 50 rpm in 900 ml of 0.1 N 
HCl, pH 6.8 Phosphate Buffer and pH 7.4 
phosphate buffer with 4 % rat cecal content. 
Simulation of gastrointestinal transit conditions 
were achieved by using different dissolution 
media. The drug release studies was conducted 
in pH 1.2 buffer solution for the first 2 h to mimic 
the condition in the stomach and in pH 6.8 
phosphate buffer for 3 h. The dissolution medium 
was then replaced with pH 7.4 phosphate buffer 
containing rat cecal content and the study 
continued for the end of 8 h. At the specified 
time, samples were withdrawn and then it was 
replaced with fresh buffer solution maintained at 
37 oC. The samples were withdrawn, diluted 
suitably and then assayed spectrophotometrically 
for the drug release at 276 nm. 
 
Kinetic analysis of drug release 
 
To determine the mechanism of drug release and 
release rate kinetics of the drug from the 
microspheres, the in vitro drug release data was 
fitted to various kinetic models representing zero-
order (Q v/s t), first-order (log (Qo–Q) v/s t), 
Higuchi’s square root of time (Q v/s t1/2) and 
Korsemeyer peppas double log plot (log Q v/s 
log t), respectively, where Q is the cumulative 
percentage of drug released at time t and (Qo–Q) 
is the cumulative percentage of drug remaining 




The results were expressed as mean ± standard 
deviations (SD). Statistical analysis was carried 
out using analysis of variance (ANOVA) on 
GraphPad Prism© 4.0 (Graphpad Software Inc. 
San Diego, CA, USA). P < 0.05 was considered 
significant. 
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In the present work, the colon specific 
microspheres of diclofenac sodium were 
prepared using solvent evaporation method. For 
the colon targeting synthetic polymers namely 
ethyl cellulose (EC), cellulose acetate phthalate 
(CAP), and Eudragit L 100-55 were used to 
prepare the microspheres. The prepared 
formulations of different drug polymer ratio were 
evaluated for physical properties like particle 
size, bulk density, tap density, angle of repose 
and percent drug encapsulation efficiency and in 




The physical parameters (Table 2) such as bulk 
density, tapping density, compressibility index 
and angle of repose were evaluated, which 
provide the basis for optimization of the flow 
property of microspheres. All the microspheres of 
various formulations showed good flow property 
with an angle of repose less than 40 o in the 
range of 28 to 35 o. Bulk density is indicative of 
the package properties of the microspheres. All 
the microspheres of different formulation were 
less than 1.2 g/ml. The size range of various 




Scanning electron microscopy reveals that F1, 
F3, F4, F5 and F6 formulation produced 
spherical microspheres as compared to F2 
formulation. The microspheres of F2 formulation 
(prepared with CAP) were of irregular shape with 
large pores and smooth surface (Fig. 1b). In the 
last formulation F6 (prepared with EC, CAP & 
Eudragit L), the microspheres were of smoothest 
surface (as compared to others) without any pore 
formation (Fig. 1d). Scanning electron 
microscopy confirmed that the microspheres of 
F1 formulation (Fig. 1a) were the spherical 
shaped with very rough surface while 
microspheres of F3, F4 and F5 formulation were 
hollow nature with small pores on the surface of 
the microspheres. Formulation F3 (prepared with 
EC and CAP) showed the presence of drug 
particles on the surface (Fig. 1c). 
 
 















repose ( o) 
F1 0.400±0.0092 0.434±0.0595 7.8341 323.50±2.1 90.88±0 .361 34.7±3.0208 
F2 0.313±0.0142 0.323±0.0063 3.0959 608.30±3.8 86.43±0 .207 34.8±1.0614 
F3 0.357±0.0248 0.416±0.0190 14.1826 426.66±1.9 91.50±0.316 26.6±0.9847 
F4 0.322±0.0248 0.344±0.0323 6.3953 533.33±1.7 78.12±0 .244 32.7±0.6112 
F5 0.318±0.0142 0.322±0.0121 2.7950 406.25±3.8 74.49±0 .173 34.6±2.4005 




Fig 1: SEM photograph of microsphere formulations (a) F1 (microspheres made of EC); (b) F2  (microspheres 
made of CAP); F3 (microspheres made of EC and CAP) and; F6  (microspheres made of EC, CAP, and Eudragit 
L 100-55 combination) 
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Fig 2: In vitro drug release study of colon specific microspheres of diclofenac sodium F1 (♦), F2 (▪), F3 (▲), F4 
(×), F5 (*), F6 (●) 
 
In vitro drug release  
 
In vitro drug release studies of all the 
formulations were performed in pH 6.8 
phosphate buffer at 276 nm (Fig 2). Drug release 
from the formulation varied significantly among 
the different polymers as well as their 
combination and ratio in the formulations. The 
drug release at the end of 8 h was 93.3, 84.82, 
90.4, 78.9, 76.6, and 69.23 % for formulation F1, 
F2, F3, F4, F5 and F6 respectively. Formulation 
F1 (followed by F3) containing ethyl cellulose 
showed the maximum release while the 
formulation F6 showed the minimum release 
after the 8 h. 
 
Kinetics of drug release 
 
The different kinetic models for diclofenac 
microspheres release were also studied. The 
release versus time curves were plotted for 
determining the order of release (zero and first 
order). It was found that the drug release was of 
zero order and followed the matrix diffusion 
process (Higuchi curves i.e. % drug release 
versus square root of time, were found linear). 
However, the formulation F2 did not show the 
linear Higuchi curves, which indicated that the 
drug release mechanism from these 





Delivering diclofenac with the colon targeting not 
only provides the high concentration in the colon 
region (where it is required at high dose in 
colorectal cancer or inflammatory bowl disease) 
but also helps to avoid the possible gastric 
irritation (which is common with immediate or 
conventional release of diclofenac) [19].  
 
All the prepared formulations showed good 
percent drug loading. The highest percent drug 
content of Formulation F3 (prepared with EC & 
CAP) was well supported by the presence of 
drug particles on the surface of these 
microspheres in its SEM. In general, SEM study 
showed spherical shaped particles with rough 
and porous surface (except that of formulation F6 
which was prepared with EC, CAP & Eudragit L). 
The drug release was very less in first 4 h and 
when the drug was exposed to the medium 
mimicking the colon, the drug release was found 
to be increasing abruptly. This lag time in drug 
release ensured the delivery of the maximum 
amount of drug in the colonic pH and colonic 
environment. The in vitro drug release study 
indicated that the combination of polymer and 
their changed ratio changed the release rate of 
drug from microspheres. The F1 formulation 
containing ethyl cellulose showed maximum 
release and F2 formulation containing CAP 
showed slow release than F1 at the same ratio of 
polymer. The ethyl cellulose formed the very 
rough surface (as confirmed by SEM) of the 
microspheres through which drug release was 
maximum by dissolving the layers of rough 
surface of polymer. The formulation F2 showed 
biphasic pattern i.e. initial fast release (as above 
50 % in only ½ h) called as burst effect, due to 
the large size of pores on the surface of 
microspheres and then sustained release due to 
smooth surface. The formulation F3 showed the 
second highest drug release after F1. This might 
be due to decrease in the concentration of EC 
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and CAP, which in turn showed the smaller pores 
on surface (as compared to EC) with little burst 
effect (due to the CAP).This indicates that the 
decrease in concentration of the both polymers 
decreased their characters like roughness, pore 
formation and burst effect (upon release). This 
was evident in SEM of F3 which showed smaller 
pores, roughness and presence of drug particles 
on the surface. The formulation F4, F5 and F6 
showed very slow release rate profile due to 
Eudragit L 100-55 (practically insoluble in water) 
polymer as compared to F1, F2 and F3. The slow 
release effect in these formulations depends on 
the concentration of the Eudragit L 100-55, which 
made the polymer solution very viscous at very 
low concentration [20]. The viscous polymer 
solution increased the coat thickness, thereby 
increasing the distance of the diffusional barrier 
for the drug [21]. Formulations F6 showed better 
sustained release as compared to others. This 
slowest release rate profile might be due to 
increased concentration of Eudragit L 100-55. 
However, increased concentration of Eudragit 
showed more uniform, spherical and smaller 
microcapsules which were evident in SEM (Fig. 
1d). Therefore, the release of diclofenac in colon 
can be targeted through these polymers in case 
of colorectal cancer where the high localization of 





Colon specific microspheres of diclofenac 
sodium using EC, CAP and Eudragit L 100-55 
have been successfully prepared. Formulation 
F3 (prepared with drug: EC: CAP in 1:2:1 ratio) is 
the optimized preparation and demonstrate 
potentially suitable drug release for the colon-
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